Friday, December 6, 2013
Pharmaceutical company Almirall has reorganized in Europe to optimize its portfolio potential. Pharmaceutical markets in Europe, particularly in Spain, have been affected in recent years by economically driven decisions made by various countries’ health authorities that have negatively affected the growth of those markets and the introduction and uptake of new products.
GlaxoSmithKline has formed the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six international cancer centers. The centers include Gustave Roussy (Villejuif, France), University of TexasMD Anderson Cancer Center (Houston), Memorial Sloan-Kettering Cancer Center (New York), Netherlands Cancer Institute, Princess Margaret Cancer Center, University Health Network (Toronto, Canada) and Vall d’Hebron Institute of Oncology-VHIO (Barcelona, Spain).
The ALS Therapy Development Institute (ALS TDI) and its wholly-owned subsidiary, Anelixis Therapeutics, a translational medicine and drug development company, have partnered with Swiss biotech company Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig’s disease.
The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children’s Research Institute, have joined forces to launch Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer.
Lexicon Pharmaceuticals has announced top-line results from an initial phase II study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
Aptuit has appointed Jonathan Goldman, M.D., as CEO. Goldman will focus on the growth of Aptuit as a provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after success at Icon Clinical Research, a global CRO specializing in the provision of clinical and other solutions that support phase I-IV clinical studies.
Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented at the annual meeting of the Radiological Society of North America (RSNA).